Tri-conference Plenary Session
The Tri-Conference has been and will continue to be a platform in recognizing the potential for new technologies and research in molecular medicine, diagnostics, drug discovery, and drug development that have a pivotal role in mitigating disease, improving access to healthcare, and identifying transformative treatments. Our plenary keynote speakers for this meeting will inspire you to continue efforts in developing novel medicines, diagnostics, therapeutics, and approaches to gain a greater understanding of the underpinnings of cancer and advance personalized medicine. Join over 750+ of your colleagues in each of these plenary keynote presentations. They are the only time each day that bring all attendees from the 14 conference tracks together in one room.
Monday, March 7
5:00 – 6:00 pm
Translating Rapid Whole Genome Sequences into Precision Medicine for Babies in Intensive Care Nurseries
Stephen F. Kingsmore, MB, ChB, BAO, DSc, FRCPath, President and CEO, Rady Pediatric Genomics & Systems Medicine Institute at Rady Children's Hospital, San Diego
Genetic diseases are the #1 cause of death in newborns in intensive care units. Rapid genome sequencing (STATseq) can diagnose genetic diseases in newborns in 26 hours. However, scaling STATseq to thousands of acutely ill newborns and implementation of precision care plans that improve outcomes are uncharted territory. Problems, potential solutions, and progress to date will be discussed.
Dr. Stephen F. Kingsmore is the President and CEO of Rady Pediatric Genomics & Systems Medicine Institute, San Diego. Dr. Kingsmore comes to Rady Children’s from Children’s Mercy Kansas City, where he most recently served as Executive Director of Medical Panomics, and from the University of Missouri, Kansas City School of Medicine where he served as Dee Lyons/Missouri Endowed Chair in Genomic Medicine. Previously Dr. Kingsmore was the founding Director of the Center for Pediatric Genomic Medicine at CM-KC, CEO of the National Center for Genome Resources, COO of Molecular Staging Inc., Vice President of Research at CuraGen Corporation, founder of GatorGen, and Assistant Professor at the University of Florida’s School of Medicine. Dr. Kingsmore received MB ChB BAO and DSc degrees from the Queen’s University of Belfast. He trained in clinical immunology in Northern Ireland and did residency in internal medicine and fellowship at Duke University Medical Center. He is a fellow of the Royal College of Pathologists. He was a MedScape Physician of the year in 2012, and received the 2013 Scripps Genomic Medicine award and 2013 ILCHUN prize of the Korean Society for Biochemistry and Molecular Biology. TIME magazine ranked his rapid genome diagnosis method one of the top 10 medical breakthroughs of 2012.
Tuesday, March 8
8:00 – 9:00 am
Unlocking the Potential of Next Generation Biomarkers
Jorge Soto, Co-founder and CTO, Miroculus
This presentation will discuss a simple, noninvasive, affordable point-of-care test that looks for early signs of multiple forms of cancer and infectious diseases based on circulating microRNAs.
Jorge, a graduate of both Tec de Monterrey and Singularity University, is co-founder and CTO of Miroculus, a life science company that aims to push forward a new test for different diseases based on circulating microRNA. Prior to founding Miroculus, he was the deputy general director of civic innovation at the coordination of national digital strategy of Mexico where he designed and launched several projects that uses technology to encourage transparency and improve the communication between citizens and their institutions.
Wednesday, March 9
8:00 – 10:00 am
Plenary Session Panel: Emerging Technologies and Industry Perspectives
Moderator: Kristin Ciriello Pothier, Head, Life Sciences, Strategy Services, Ernst & Young
Panelist: Bernard Andruss, Ph.D., Vice President, Diagnostic Development, Asuragen
Panelist: Paul Diehl, Director of Business Development, Cellecta, Inc.
Additional Panelists to be Announced
This panel session will feature a series of presentations on emerging and hot technologies in molecular medicine. Each speaker will have 7 minutes at the podium. After all speakers have presented, there will be a moderated Q&A with attendees. The presentations are not meant to be a corporate or specific product pitch. Each speaker will focus on a technology and solution framed around a motivational clinical problem and how their particular company/organization is solving it.